Filter by Lead Doctor (All Doctors) Parvin Peddi, M.D.Janie Grumley, M.D.Erwin Grussie, M.D. Title Physician HR+HER2- Breast Cancer NCT ID : 04895761 Protocol Number : IMV P2100-SUR-S11 Phase : 1 Location : Saint John's Cancer Institute Parvin Peddi, M.D. Known Metastatic Breast Cancer with ER-Positive and HER2-Negative Primary Lesions NCT ID : 05068726 Protocol Number : GE-280-401 Phase : 4 Location : Saint John's Cancer Institute Parvin Peddi, M.D. Biomarker Low Risk Node Positive Breast Cancer: TAILOR RT. NCT ID : 03488693 Protocol Number : CCTGMA.39 Phase : 3 Location : Santa Monica, CA Janie Grumley, M.D. Locally Advanced or Metastatic HR+/HER2- Breast Cancer NCT ID : 04851613 Protocol Number : LAE205INT3101 Phase : Phase Ib/II Location : Saint John's Cancer Institute Parvin Peddi, M.D. Unresectable, Locally Advanced or Metastatic Triple-Negative Breast Cancer NCT ID : 04958785 Protocol Number : GS-US-586-6144 Phase : 2 Location : Saint John's Cancer Institute Parvin Peddi, M.D. THE COMPASSHER2 TRIALS (COMPREHENSIVE USE OF PATHOLOGIC RESPONSE ASSESSMENT TO OPTIMIZE THERAPY IN HER2-POSITIVE BREAST CANCER): COMPASSHER2 Residual Disease (RD), A Double-Blinded, PHASE III Randomized Trial Of T-DM1 And Placebo Compared With T-DM1 And TUCATINIB NCT ID : 04457596 Protocol Number : A011801 Phase : Phase III Location : Saint John's Cancer Institute Parvin Peddi, M.D. Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases (SWOG) NCT ID : 04647916 Protocol Number : S2007 Phase : 2 Location : Saint John's Cancer Institute Parvin Peddi, M.D. A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy (Astefania) NCT ID : 04873362 Protocol Number : WO42633 Phase : 3 Location : Disney Family Cancer Center Erwin Grussie, M.D.
